Carmignac Gestion Clovis Oncology, Inc. Transaction History

Carmignac Gestion

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$11.63 - $32.67 $17.6 Million - $49.5 Million	-1,514,940 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$29.37 - $49.48 $190,905 - $321,620	-6,500 Reduced 0.43%	1,514,940 $44.5 Million
Q2 2018 Aug 13, 2018	BUY	$42.06 - $62.4 $500,514 - $742,560	11,900 Added 0.79%	1,521,440 $69.2 Million
Q1 2018 May 14, 2018	BUY	$50.12 - $67.72 $9.46 Million - $12.8 Million	188,676 Added 14.28%	1,509,540 $79.7 Million
Q4 2017 Feb 13, 2018	BUY	$57.69 - $84.58 $76.2 Million - $112 Million	1,320,864	1,320,864 $89.8 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.